Anavex Life Sciences is a clinical stage biopharmaceutical company engaged in the development of therapeutics by applying medicine to central nervous system (CNS) diseases. Co.'s primary compound, ANAVEX®2-73, is being developed to treat Alzheimer's disease, Parkinson's disease and other CNS diseases, including rare diseases, such as Rett syndrome. Co.'s proprietary SIGMACEPTOR Discovery Platform produced small molecule drug candidates with certain modes of action, based on its understanding of sigma receptors. Compounds that have been subjects of Co.'s research include the following: ANAVEX®3-71, ANAVEX®1-41, ANAVEX®1066, and ANAVEX®1037. The AVXL stock yearly return is shown above.
The yearly return on the AVXL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AVXL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|